These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 2911842

  • 1. Interaction between digoxin and propafenone.
    Calvo MV, Martin-Suarez A, Martin Luengo C, Avila C, Cascon M, Domínguez-Gil Hurlé A.
    Ther Drug Monit; 1989; 11(1):10-5. PubMed ID: 2911842
    [Abstract] [Full Text] [Related]

  • 2. [Digoxin-propafenone interaction: values and limitations of plasma determination of the 2 drugs. Anti-arrhythmia effectiveness of propafenone].
    Palumbo E, Svetoni N, Casini M, Spargi T, Biagi G, Martelli F, Lanzetta T.
    G Ital Cardiol; 1986 Oct; 16(10):855-62. PubMed ID: 3817368
    [Abstract] [Full Text] [Related]

  • 3. Effect of diprafenone on the pharmacokinetics of digoxin.
    Koytchev R, Alken RG, Mayer O.
    Eur J Clin Pharmacol; 1996 Oct; 50(1-2):97-100. PubMed ID: 8739818
    [Abstract] [Full Text] [Related]

  • 4. Effects of coadministration of propafenone on the pharmacokinetics of digoxin in healthy volunteer subjects.
    Nolan PE, Marcus FI, Erstad BL, Hoyer GL, Furman C, Kirsten EB.
    J Clin Pharmacol; 1989 Jan; 29(1):46-52. PubMed ID: 2708548
    [Abstract] [Full Text] [Related]

  • 5. The digoxin-propafenone interaction: characterization of a mechanism using renal tubular cell monolayers.
    Woodland C, Verjee Z, Giesbrecht E, Koren G, Ito S.
    J Pharmacol Exp Ther; 1997 Oct; 283(1):39-45. PubMed ID: 9336306
    [Abstract] [Full Text] [Related]

  • 6. Serum digoxin levels related to plasma propafenone levels during concomitant treatment.
    Bigot MC, Debruyne D, Bonnefoy L, Grollier G, Moulin M, Potier JC.
    J Clin Pharmacol; 1991 Jun; 31(6):521-6. PubMed ID: 1880217
    [Abstract] [Full Text] [Related]

  • 7. Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure.
    DiDomenico RJ, Bress AP, Na-Thalang K, Tsao YY, Groo VL, Deyo KL, Patel SR, Bishop JR, Bauman JL.
    Pharmacotherapy; 2014 Nov; 34(11):1121-31. PubMed ID: 25164709
    [Abstract] [Full Text] [Related]

  • 8. Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein.
    Bachmakov I, Rekersbrink S, Hofmann U, Eichelbaum M, Fromm MF.
    Naunyn Schmiedebergs Arch Pharmacol; 2005 Mar; 371(3):195-201. PubMed ID: 15900513
    [Abstract] [Full Text] [Related]

  • 9. Digoxin and bepridil: pharmacokinetic and pharmacodynamic interactions.
    Belz GG, Wistuba S, Matthews JH.
    Clin Pharmacol Ther; 1986 Jan; 39(1):65-71. PubMed ID: 3484691
    [Abstract] [Full Text] [Related]

  • 10. Association of serum digoxin concentration and outcomes in patients with heart failure.
    Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM.
    JAMA; 2003 Feb 19; 289(7):871-8. PubMed ID: 12588271
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
    Labbé L, O'Hara G, Lefebvre M, Lessard E, Gilbert M, Adedoyin A, Champagne J, Hamelin B, Turgeon J.
    Clin Pharmacol Ther; 2000 Jul 19; 68(1):44-57. PubMed ID: 10945315
    [Abstract] [Full Text] [Related]

  • 12. [Effect of propafenone on the pharmacokinetics of digoxin administered orally: a study in healthy volunteers].
    Cardaioli P, Compostella L, De Domenico R, Papalia D, Zeppellini R, Libardoni M, Pulido E, Cucchini F.
    G Ital Cardiol; 1986 Mar 19; 16(3):237-40. PubMed ID: 3732716
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic interaction of sparfloxacin and digoxin.
    Johnson RD, Dorr MB, Hunt TL, Conway S, Talbot GH.
    Clin Ther; 1999 Feb 19; 21(2):368-79. PubMed ID: 10211539
    [Abstract] [Full Text] [Related]

  • 14. Effect of aging on the incidence of digoxin toxicity.
    Miura T, Kojima R, Sugiura Y, Mizutani M, Takatsu F, Suzuki Y.
    Ann Pharmacother; 2000 Apr 19; 34(4):427-32. PubMed ID: 10772425
    [Abstract] [Full Text] [Related]

  • 15. Quinidine-digoxin interaction: evidence for involvement of an extrarenal mechanism.
    Doering W, Fichtl B, Herrmann M, Besenfelder E.
    Eur J Clin Pharmacol; 1982 Apr 19; 21(4):281-5. PubMed ID: 7056272
    [Abstract] [Full Text] [Related]

  • 16. Quinidine-digoxin interaction: cardiac efficacy of elevated serum digoxin concentration.
    Belz GG, Doering W, Aust PE, Heinz M, Matthews J, Schneider B.
    Clin Pharmacol Ther; 1982 May 19; 31(5):548-54. PubMed ID: 7075104
    [Abstract] [Full Text] [Related]

  • 17. Clinical pharmacokinetics of propafenone.
    Hii JT, Duff HJ, Burgess ED.
    Clin Pharmacokinet; 1991 Jul 19; 21(1):1-10. PubMed ID: 1914339
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic and pharmacodynamic evaluation of propafenone in patients with ventricular arrhythmia. Propafenone Research Group.
    Zoble RG, Kirsten EB, Brewington J.
    Clin Pharmacol Ther; 1989 May 19; 45(5):535-41. PubMed ID: 2721109
    [Abstract] [Full Text] [Related]

  • 19. A model for the prediction of digoxin-drug interactions at the renal tubular cell level.
    Woodland C, Ito S, Koren G.
    Ther Drug Monit; 1998 Apr 19; 20(2):134-8. PubMed ID: 9558126
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine.
    Pritchett EL, Smith WM, Kirsten EB.
    J Clin Pharmacol; 1988 Jul 19; 28(7):619-24. PubMed ID: 3063727
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.